Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by George Bondi on Nov 9th, 2026

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.63.

ATEC has been the topic of several research reports. Wall Street Zen cut shares of Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. UBS Group lowered shares of Alphatec from a “buy” rating to a “neutral” rating and decreased their target price for the company from $15.00 to $8.50 in a research note on Wednesday, November 4th. BMO Capital Markets lowered shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 target price for the company. in a research note on Friday, October 30th. TD Cowen dropped their target price on Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. cut their price target on Alphatec from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, October 30th.

View Our Latest Research Report on ATEC

Insider Activity at Alphatec

In other Alphatec news, Director David M. Demski bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was bought at an average cost of $6.81 per share, for a total transaction of $408,600.00. Following the completion of the transaction, the director owned 491,635 shares of the company’s stock, valued at $3,348,034.35. This represents a 13.90% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles bought 115,000 shares of Alphatec stock in a transaction on Thursday, September 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the acquisition, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. The trade was a 1.99% increase in their position. The disclosure for this purchase is available in the SEC filing. 13.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alphatec

Institutional investors have recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY bought a new position in shares of Alphatec in the second quarter worth about $9,413,000. Bank of America Corp DE grew its position in shares of Alphatec by 26.9% during the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after purchasing an additional 543,059 shares in the last quarter. FirstWave Capital Management LLC bought a new stake in Alphatec during the 2nd quarter valued at approximately $1,244,000. Emerald Advisers LLC raised its stake in Alphatec by 10.4% during the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after purchasing an additional 169,578 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Alphatec during the 2nd quarter valued at approximately $3,092,000. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Performance

NASDAQ ATEC opened at $7.44 on Wednesday. Alphatec has a one year low of $6.81 and a one year high of $23.29. The stock has a 50-day moving average of $9.97 and a 200 day moving average of $10.38. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -13.53 and a beta of 0.88.

Alphatec (NASDAQ:ATEC – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The company had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. During the same quarter in the prior year, the company posted $0.03 EPS. Alphatec’s revenue was up 12.6% on a year-over-year basis. On average, equities analysts predict that Alphatec will post -0.40 earnings per share for the current fiscal year.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.